Healthcare · FORH
Hospitals
from 955 today
Fortis Healthcare reported in-line EBITDA growth, with further margin improvement expected from case and payor mix, cost rationalization, and recent hospital acquisitions and additions. We maintain our BUY rating with a target price of INR 1,120 per share.
Fortis delivered strong operational performance in Q1FY27 with robust revenue growth, resilient margin outlook, and ongoing turnarounds in Agilus Diagnostics.
Ratings and target prices as published by each firm. Each summary condenses that firm's stated view in its own note and is attributed to it; no report text is reproduced.
